Navigation Links
Tomophase to Exhibit First In-vivo Cross-sectional Images of Pulmonary Stenting Using Proprietary OCT System
Date:10/21/2008

Results to be displayed at CHEST meeting in October

BURLINGTON, Mass., Oct. 21 /PRNewswire/ -- Tomophase Corporation announced today that it will display the first in-vivo cross-sectional images of implanted pulmonary stents using their proprietary optical coherence tomography (OCT) system at the CHEST meeting in Philadelphia, Oct. 27th through Oct. 29th. The images were captured using the Tomophase OCT System as part of an ongoing research collaboration with Dr. Armin Ernst, Director of Interventional Pulmonology and Dr. Hisashi Tsukada, Research Associate, at Beth Israel Deaconess Medical Center in Boston, Massachusetts.

The Tomophase OCT System enables the interventional pulmonologist to clearly visualize sub-epithelial tissue structures in the airway. The system, which is not yet FDA-approved, utilizes a near-infrared emitting probe in a catheter which is integrated with a conventional video bronchoscope. The images captured by the research team at Beth Israel are from in-vivo animal model tracheal tissue. During the next several months, the company plans to continue this work as it progresses towards use of the system in human clinical studies.

"Our goal at Tomophase is to use our proprietary optical technology to help clinicians image subsurface pulmonary tissue at a level of resolution currently unavailable, while not exposing the patient to potentially harmful radiation, UV light or contrast agents," commented Dr. Peter Norris, CEO of Tomophase. "Much of the structure in the airways beneath the epithelial layer is essentially invisible to clinicians. Providing real-time access to this information could provide major benefits to both diagnostic and therapeutic approaches to many pulmonary diseases. We believe this research collaboration with Beth Israel Deaconess is an important first step in establishing the utility of this breakthrough technology in both research and the clinic."

"These latest imaging results from the Tomophase OCT system show excellent detail in the region surrounding the implanted stent," commented Dr. Ernst. "As such, it may ultimately prove very useful to clinicians in understanding the detailed nature of the interaction between the stent material, including those made from bio-absorbable materials, and the surrounding tissue. High-resolution, cross-sectional OCT imaging technology may also have the potential to provide real-time evaluation of other drug and device/tissue interactions as well."

About Tomophase Corporation

Tomophase Corporation is a private company founded in 2003 based on proprietary technology innovations in the field of optical coherence tomography and its use to image tissue at high resolution. With Tomophase OCT, researchers and clinicians can observe tissue structure within 2-3 mm of the surface without the use of radiation, UV light or image contrast agents. Tomophase is pursuing the first application of its technology in pulmonary medicine for the visualization of airways. Future development areas include respiratory therapy development, lung cancer management and surgical guidance.

More information on Tomophase Corporation can be found at http://www.tomophase.com.

For further information:

Dr. Peter Norris, CEO

Tomophase Corporation

1 North Ave., Burlington, MA 01803

P: (781) 229-5700 x122

E: pnorris@tompohase.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Tomophase Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Milestone Scientific to Exhibit the STA(TM) System at the American Dental Associations 148th Annual Session in San Francisco
2. Worlds Largest Exhibit of Princess Dianas Dresses Hosted by Appleton Museum
3. Sesame Street Exhibition Makes Texas Premier at The Health Museum
4. CRH Medical to exhibit at American College of Surgeons Annual Clinical Congress
5. CareTech Solutions Executive to Conduct Presentation on Creating a Healthy Revenue Cycle at AHIMA Convention and Exhibit
6. Global Med Technologies(R), Inc.s Division, Wyndgate Technologies(R), to Exhibit at 60th Annual AABB Conference
7. Our Body: The Universe Within Exhibition Announces Four New Exhibits Across The Nation
8. Inovis Sponsors ASC X12 Conference, Exhibits BizManager and Secure Link
9. Hooper Holmes to Exhibit at the 2007 Sixth Annual Association of Home Office Underwriters Conference
10. The Justin Gimelstob Childrens Fund Hosts Tennis Exhibition
11. NASA Astronauts, Exercise Exhibit To Be At Houston Marathon Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... As part of their 2015 end of year ... Table Foundation (MDRTF), has gifted $10,000 to University of Chicago to support ovarian cancer ... Cundiff. , “We are honored to support a promising young investigator from Dr. Lengyel’s ...
(Date:2/10/2016)... ... February 10, 2016 , ... The ... World Molecular Imaging Congress (WMIC), will be held in New York City, NY ... “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize how imaging reveals a ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Early this week, ... and raise awareness of Nestlé KITKAT as the first global confectionery brand sourced from ... cocoa farmers and the quality of their product, through activities that focus on better ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... care communications company offering education, research and medical media, has launched ... working in infectious diseases. , As the all-inclusive resource for infectious disease ...
(Date:2/10/2016)... Walton Beach, Florida (PRWEB) , ... February 10, ... ... the innovative weather-forecasting company is unveiling its revolutionary new 2.0 version at the ... platform, MetLoop has “put the power of the world's most advanced weather technology ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... fourth quarter and full year ended December 31, 2015. ... was a transformational year for Vanda with the continued ... market approval of HETLIOZ for Non-24," said Mihael H. ... Fanapt to our U.S. product portfolio builds on this ...
(Date:2/10/2016)... , February 10, 2016 ... Analyzers (Liquid & Gas), and Spectroscopy Market by Industry (Oil ... Beverage, Pulp & Paper, Metal & Mining, and Others), ... MarketsandMarkets, the global market is expected to grow to ... of 8.6% between 2015 and 2020. Browse ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
Breaking Medicine Technology: